Mnta Big News - Pwrm, Hway Reported By Pennytobuck.com
Power 3 Medical Products Inc
Power 3 Medical Products Inc. (OTC BB: PWRM) recently has unexpectedly discovered new and unprecedented findings regarding clinically important differences in the response of the NuroPro protein biomarkers in the blood of untreated Alzheimers disease patients compared to patients treated with the widely used anti-dementia drugs Aricept (Donepezil HCl, Pfizer NYSE: PFE), Exelon (Rivastigmine, Novartis NYSE: NVS), and Namenda (Memantine HCl, Forest Laboratories NYSE: FRX). These results relate to the genetically distinct groups of Alzheimers disease patients, i.e., those individuals who possess the Alzheimers high-risk gene for Apolipoprotein E4 and those who do not possess the gene. PWRMs NuroPro was originally indicated for diagnostics to determine whether or not a patient had Alzheimers disease. With these results, PWRMs NuroPro now extends into the pharmaceutical arena due to its ability to predict and monitor the response to drug treatment, including the underlying disease process and the insidious progression of irreversible neurological damage, even in the face of temporary improvements in cognition and other symptoms.
Healthways, Inc. (NASDAQ: HWAY) reported financial results for the second quarter ended June 30, 2010. Total revenues for the quarter were $175.5 million compared with $177.8 million for the second quarter of 2009. Net income for the second quarter of 2010 was $11.8 million, or $0.34 per diluted share, compared with $8.9 million, or $0.26 per diluted share, for the second quarter of 2009. Results for the second quarter of 2010 included earnings of $0.05 per diluted share attributable to an adjustment to an estimated earn-out liability and an investment gain. Excluding these items, adjusted earnings per diluted share totaled $0.29, an 11.5% increase over the second quarter of 2009.
Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that the U.S. Food and Drug Administration has granted marketing approval of the Abbreviated New Drug Application (ANDA) for enoxaparin sodium for injection filed by Sandoz. Developed under a collaboration agreement between Momenta and Sandoz, this product has been designated therapeutically equivalent to the reference-listed drug, Lovenox(R), which is marketed by Sanofi-Aventis.
Momenta Pharmaceuticals is a biotechnology company, headquartered in Cambridge, MA, specializing in the detailed structural analysis of complex mixture drugs. Momenta is applying its technology to the development of generic versions of complex drug products, as well as to the discovery and development of novel drugs.
To receive additional information about Momenta, please visit the website at www.momentapharma.com, which does not form a part of this press release.
For FREE Daily Stock Alerts & Updates Signup At: http://pennytobuck.com/signup
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. PennyToBuck.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers.Our disclaimer (http://pennytobuck.com/disclaimer) is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold PennyToBuck.com report and Crown Equity Holdings, Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (CRWE.OB) has previously received five hundred thousand shares compensation for 30 days of advertisement services and received an additional 1,000,000 shares 144 restricted stocks for a continuation of 6 months of advertisement and disseminating news, as well as $15,000 dollars for IR services for Power 3 Medical Products Inc. (PWRM.OB). Recently, Crown Equity Holdings, Inc has received an additional amount of 2,000,000 shares of free trading stock for 60 days media advertisement, web design and maintenance for Power 3 Medical Products Inc. (PWRM.OB)
by: Bill Pennyman
How to make millions with runescape Best Places To See In Los Angeles Know About Shock Absorbers 000-047 dumps Jan Berkowitz Excited to a Member of St. Jude Partner In Hope Program Scentsy Candles Are Safe & Flameless What Is Past Life Healing? Get Out Of Your Comfort Zone How Mark Ling's Affilojetpack May Help You Achieve Success 3 Days Zoo Mystery Free Accident Claims Advice: A Guide To Fatal Accident Claims How Safe Are Fixed Annuities? Construction Accident Claims Advice